

Alessandro Pileri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2886216/publications.pdf>

Version: 2024-02-01

306
papers

10,275
citations

43973

48
h-index

40881

93
g-index

315
all docs

315
docs citations

315
times ranked

6140
citing authors

#	ARTICLE	IF	CITATIONS
1	Estimating the incidence of COVID-19 skin manifestations on the general population in a territorial setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	0
2	Prognostic significance of Bcl-2 expression in primary cutaneous B-cell lymphoma: a reappraisal. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 156, .	0.1	1
3	Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management. <i>Presse Medicale</i> , 2022, 51, 104109.	0.8	8
4	Mycosis fungoides involving the genital area. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 156, .	0.1	1
5	Who is the culprit? A toxic epidermal necrolysis case in a patient treated with rituximab plus polatuzumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
6	A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	4
7	BCL2 expression in primary cutaneous follicle center lymphoma is associated with a higher risk of cutaneous relapses: A study of 126 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	2
8	TOX Expression in Mycosis Fungoides and Sezary Syndrome. <i>Diagnostics</i> , 2022, 12, 1582.	1.3	2
9	Is Dermoscopy Useful for the Diagnosis of Pseudolymphomas?. <i>Dermatology</i> , 2021, 237, 213-216.	0.9	4
10	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2021, 141, 484-495.	0.3	31
11	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 99-102.	0.4	2
12	Bullous Wells Syndrome: a needle in the haystack. <i>International Journal of Dermatology</i> , 2021, 60, e150-e153.	0.5	0
13	Red dye-related tattoo reactions: Could optical coherence tomography be of help?. <i>Skin Research and Technology</i> , 2021, 27, 469-471.	0.8	0
14	A pink nodule on the left subscapular region in an 8-year-old girl. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 620-622.	0.4	0
15	Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 961-968.	1.4	5
16	Italian expert-based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an eDelphi consensus. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2021, 37, 334-342.	0.7	4
17	Chilblain lesions after COVID-19 mRNA vaccine. <i>British Journal of Dermatology</i> , 2021, 185, e3.	1.4	20
18	Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. <i>Scientific Reports</i> , 2021, 11, 10555.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Inâ€depth, singleâ€centre, analysis of changes in emergency service access after the spread of COVIDâ€19 across Italy. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1588-1589.	0.6	1
20	Dimethyl fumarate: a case of improvement of alcoholic steatohepatitis in an elderly psoriatic patient. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.1	1
21	Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 733770.	1.3	13
22	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021, 13, 4680.	1.7	6
23	Erythroderma: psoriasis or lymphoma? A diagnostic challenge and therapeutic pitfall. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.1	2
24	Second neoplasm in cutaneous T-cell lymphoma patients: a marker of worse prognosis?. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	1
25	The Microenvironmentâ€™s Role in Mycosis Fungoides and SÃ©zary Syndrome: From Progression to Therapeutic Implications. <i>Cells</i> , 2021, 10, 2780.	1.8	17
26	Iatrogenic Kaposi sarcoma during tumor necrosis factor alpha inhibitors. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 113-114.	0.1	0
27	Pityriasis lichenoides triggered by measlesâ€mumpsâ€rubella vaccine injection. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 758-760.	0.4	7
28	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. <i>Hematological Oncology</i> , 2020, 38, 831-833.	0.8	1
29	Cutaneous adverseâ€events in patients treated with Ibrutinib. <i>Dermatologic Therapy</i> , 2020, 33, e14190.	0.8	7
30	Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 833-854.	3.3	25
31	BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role. <i>Frontiers in Oncology</i> , 2020, 10, 662.	1.3	8
32	Herpes zoster in COVIDâ€19â€positive patients. <i>International Journal of Dermatology</i> , 2020, 59, 1028-1029.	0.5	93
33	Changes in emergency service access after spread of COVIDâ€19 across Italy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e350-e351.	1.3	19
34	Granulomatous tattoo reaction in a nivolumab-treated patient. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 530-532.	0.8	1
35	Merkel cell carcinoma: a prompt diagnosis to increase survival. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e478-e480.	1.3	0
36	Asymptomatische brÃ¼nliche LÃ©sionen an Armen und Beinen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 659-662.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Brownish asymptomatic lesions on the arms and legs. JDDG - Journal of the German Society of Dermatology, 2019, 17, 659-662.	0.4	1
38	Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e367-e369.	1.3	5
39	Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers, 2019, 11, 595.	1.7	70
40	New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia. British Journal of Dermatology, 2019, 180, 1535-1536.	1.4	6
41	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica, 2019, 104, 729-737.	1.7	58
42	Primary cutaneous B-cell lymphoma: narrative review of the literature. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 466-479.	0.8	6
43	Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukemia patients. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 605-606.	0.8	3
44	SÅžary Syndrome without erythroderma featuring a CD30+ progression. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 494-495.	0.8	0
45	Verrucous mycosis fungoides. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 504-505.	0.8	1
46	Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. Italian Journal of Dermatology and Venereology, 2019, , .	0.1	0
47	Primary cutaneous CD8+ CD30+ lymphoproliferative disorder in a patient with acquired CD4 immunodeficiency. Italian Journal of Dermatology and Venereology, 2019, , .	0.1	0
48	Primary cutaneous peripheral Tâ€cell lymphoma not otherwise specified a rare and aggressive lymphoma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e373-e376.	1.3	5
49	Primary cutaneous small/medium-sized pleomorphic Tâ€cell lymphoproliferative disorder shows a common vascular pattern at dermoscopy. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e318-e321.	1.3	8
50	A large mass and erythematousâ€violaceous plaques. JDDG - Journal of the German Society of Dermatology, 2018, 16, 372-375.	0.4	0
51	The role of myeloid derived suppressor cells in mycosis fungoides. Cancer Immunology, Immunotherapy, 2018, 67, 1175-1176.	2.0	2
52	Plaques and tumors in a patient with refractory SÅžary syndrome treated with mogamulizumab. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1263-1265.	0.4	3
53	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Annals of Oncology, 2018, 29, 2363-2370.	0.6	89
54	Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktÃrem SÅžary-Syndrom. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1263-1266.	0.4	1

#	ARTICLE	IF	CITATIONS
55	An Asymptomatic Plaque on the Chest: A Quiz. <i>Acta Dermato-Venereologica</i> , 2018, 98, 294-296.	0.6	0
56	Erythematöse Plaques und Tumoren im Gesicht und an den Armen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1162-1165.	0.4	0
57	Erythematous plaques and tumors on the face and arms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1162-1164.	0.4	0
58	Ein großer Tumor und livide erythematöse Plaques. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 372-375.	0.4	0
59	Dermatofibrosarcoma protuberans secondary to a decorative tattoo: An Isotattootopic Response?. <i>Indian Journal of Dermatology</i> , 2018, 63, 439.	0.1	4
60	Alopecia areata-like mycosis fungoides: lions for lambs. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 293-295.	0.1	2
61	Squamous cell carcinoma developed after ingenol mebutate therapy: a possible consequence of the treatment?. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 442-443.	0.1	1
62	Idiopathic follicular mucinosis: can dermoscopy be helpful?. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 440-441.	0.1	0
63	Extramedullary metastatic plasmacytoma in multiple myeloma. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 741-743.	0.8	0
64	Leukemia cutis in a Ph+ ALL patient treated with ponatinib. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 730-731.	0.8	0
65	Maintenance phase in psoralen-ultraviolet A phototherapy of early-stage mycosis fungoides. A critically appraised topic. <i>British Journal of Dermatology</i> , 2017, 177, 406-410.	1.4	14
66	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. <i>Molecular Cancer Research</i> , 2017, 15, 541-552.	1.5	24
67	Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome?. <i>European Journal of Dermatology</i> , 2017, 27, 49-53.	0.3	8
68	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 575-582.	1.4	20
69	Photodynamic therapy: An option in mycosis fungoides. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 20, 107-110.	1.3	12
70	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
71	Erosive pustular dermatosis of the leg: an uncommon entity?. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 675-678.	0.1	3
72	Vemurafenib mucosal side effect. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1053-1055.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 715-718.	2.3	28
74	Erythematous induration of the chest. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1291-1293.	0.4	1
75	Erythematöse Induration im Brustbereich. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1291-1293.	0.4	0
76	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
77	Vascular endothelial growth factor A (<sc>VEGFA</sc>) expression in mycosis fungoides. <i>Histopathology</i> , 2015, 66, 173-181.	1.6	14
78	Bosentan and Extracorporeal Photochemotherapy in Eosinophilic Fasciitis. <i>International Journal of Lower Extremity Wounds</i> , 2014, 13, 160-161.	0.6	6
79	Large granular lymphocytic leukaemia mimicking ulcer of the lower limb. <i>International Wound Journal</i> , 2014, 11, 104-105.	1.3	1
80	Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-κB pathway inhibition. <i>Leukemia</i> , 2014, 28, 1606-1616.	3.3	164
81	Annular lesions located on the right forearm. <i>Indian Journal of Dermatology</i> , 2014, 59, 636.	0.1	0
82	Multiple familial trichodiscomas. <i>Cutis</i> , 2014, 93, E6-7.	0.4	1
83	Chilblain lupus erythematosus in a patient affected by <sc>H</sc> Hodgkin lymphoma. <i>Australasian Journal of Dermatology</i> , 2013, 54, 74-75.	0.4	0
84	Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides. <i>Immunotherapy</i> , 2013, 5, 427-433.	1.0	34
85	Persistent Agmination of Lymphomatoid Papulosis: An Ongoing Debate. <i>Dermatology</i> , 2012, 225, 131-134.	0.9	8
86	Mycosis fungoides following pityriasis lichenoides: An exceptional event or a potential evolution. <i>Pediatric Blood and Cancer</i> , 2012, 58, 306-306.	0.8	12
87	Mycosis fungoides: disease evolution of the "lion queen" revisited. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2012, 147, 523-31.	0.8	12
88	Combination treatment in CTCL: the current role of bexarotene. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2012, 147, 573-80.	0.8	5
89	Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2012, 147, 603-8.	0.8	18
90	Lymphoma classification: the quiet after the storm. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 113-123.	1.0	20

#	ARTICLE	IF	CITATIONS
91	Primary cutaneous lymphomas: a reprisal. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 214-233.	1.0	17
92	Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS). <i>European Journal of Dermatology</i> , 2011, 21, 624-625.	0.3	9
93	Syringotropic Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2011, 35, 100-109.	2.1	59
94	Atypical piloleiomyoma of the face presenting with central ulceration. <i>Dermatology Reports</i> , 2011, 3, e50.	0.4	5
95	Primary Cutaneous Large B-Cell Lymphoma, Leg Type, Localized on the Dorsum. <i>Case Reports in Dermatology</i> , 2009, 1, 87-92.	0.3	3
96	Tattoo-associated Pseudolymphomatous Reaction and its Successful Treatment with Hydroxychloroquine. <i>Acta Dermato-Venereologica</i> , 2009, 89, 327-328.	0.6	24
97	Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. <i>Clinical and Experimental Immunology</i> , 2008, 79, 100-104.	1.1	23
98	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.	0.8	68
99	Prospective, multicenter randomized GITMO/IIIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
100	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. <i>Leukemia</i> , 2007, 21, 340-350.	3.3	571
101	Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 1376-1382.	0.8	199
102	Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. <i>Histopathology</i> , 2005, 47, 645-646.	1.6	3
103	The karma of Kikuchi's disease. <i>Clinical Immunology</i> , 2005, 114, 27-29.	1.4	17
104	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. <i>Journal of Clinical Oncology</i> , 2004, 22, 1460-1468.	0.8	116
105	Indolent lymphoma: the pathologist's viewpoint. <i>Annals of Oncology</i> , 2004, 15, 12-18.	0.6	17
106	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. <i>Leukemia</i> , 2004, 18, 139-145.	3.3	63
107	High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. <i>Cancer</i> , 2003, 97, 2748-2759.	2.0	71
108	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. <i>Cancer</i> , 2003, 98, 983-992.	2.0	18

#	ARTICLE	IF	CITATIONS
109	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2003, 31, 767-773.	1.3	15
110	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1398-1403.	0.8	35
111	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i> , 2002, 99, 75-82.	0.6	147
112	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002, 100, 1559-1565.	0.6	89
113	Real-time polymerase chain reaction in multiple myeloma. <i>Experimental Hematology</i> , 2002, 30, 529-536.	0.2	24
114	Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: Non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2002, 81, 448-453.	0.8	20
115	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. <i>British Journal of Haematology</i> , 2002, 117, 642-645.	1.2	11
116	High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. <i>Bone Marrow Transplantation</i> , 2002, 30, 725-732.	1.3	47
117	Hodgkin's lymphoma: the pathologist's viewpoint. <i>Journal of Clinical Pathology</i> , 2002, 55, 162-176.	1.0	189
118	Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and Molecular Remission at Six Years Since Autografting. <i>Leukemia and Lymphoma</i> , 2001, 40, 679-682.	0.6	6
119	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. <i>British Journal of Haematology</i> , 2001, 113, 1051-1059.	1.2	48
120	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. <i>Leukemia</i> , 2001, 15, 256-263.	3.3	28
121	Growth advantage of chronic myeloid leukemia CFU-GM in vitro : survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids±interferon. <i>Leukemia</i> , 2001, 15, 422-429.	3.3	7
122	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 1941-1949.	3.3	49
123	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. <i>Experimental Hematology</i> , 2001, 29, 183-193.	0.2	64
124	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 46-53.	1.2	16
125	Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. <i>Bone Marrow Transplantation</i> , 2000, 26, 1185-1191.	1.3	59
126	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. <i>Leukemia</i> , 2000, 14, 740-747.	3.3	35

#	ARTICLE	IF	CITATIONS
127	Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. <i>Bone Marrow Transplantation</i> , 2000, 25, 25-29.	1.3	24
128	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. <i>Medical Oncology</i> , 2000, 17, 203-210.	1.2	27
129	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	201
130	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	1
131	Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells. <i>Journal of Clinical Oncology</i> , 1999, 17, 208-208.	0.8	222
132	Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. <i>Blood</i> , 1999, 94, 1248-1253.	0.6	152
133	Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients. <i>Stem Cells</i> , 1999, 17, 55-61.	1.4	26
134	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. <i>Leukemia</i> , 1999, 13, 1456-1462.	3.3	37
135	Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies. <i>Leukemia</i> , 1999, 13, 1691-1695.	3.3	42
136	Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. <i>Annals of Hematology</i> , 1999, 78, 539-543.	0.8	97
137	Modulation of in vitro chemosensitivity in acute myelogenous leukemia cell line by GM-CSF: opposing effects observed with different cytotoxic drugs and time exposure. <i>Leukemia Research</i> , 1999, 23, 931-938.	0.4	4
138	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	127
139	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	2
140	Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. <i>Blood</i> , 1999, 94, 1248-1253.	0.6	1
141	A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation. <i>Bone Marrow Transplantation</i> , 1998, 21, 409-413.	1.3	11
142	G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. <i>Bone Marrow Transplantation</i> , 1998, 21, 401-407.	1.3	55
143	Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 449-455.	1.3	48
144	The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 127-134.	1.0	48

#	ARTICLE	IF	CITATIONS
145	The Italian Experience on Interferon as Maintenance Treatment in Multiple Myeloma: Ten Years After. <i>Blood</i> , 1998, 92, 2184-2186.	0.6	14
146	High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 1997, 336, 1290-1298.	13.9	460
147	DIAGNOSIS, PROGNOSIS, AND STANDARD TREATMENT OF MULTIPLE MYELOMA. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 111-131.	0.9	67
148	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. <i>Blood</i> , 1997, 89, 724-491.	0.6	158
149	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997, 11, 1793-1798.	3.3	99
150	Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. <i>Bone Marrow Transplantation</i> , 1997, 19, 23-29.	1.3	15
151	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. <i>Bone Marrow Transplantation</i> , 1997, 20, 341-343.	1.3	7
152	Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: Modulating effects of dihydroxylated vitamin D3, β -interferon and α -stem cell factor [™] . <i>Leukemia Research</i> , 1997, 21, 51-58.	0.4	8
153	DISTRIBUTION OF T α CELL SIGNALING MOLECULES IN HUMAN MYELOMA. <i>British Journal of Haematology</i> , 1997, 97, 810-814.	1.2	100
154	Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. <i>British Journal of Haematology</i> , 1997, 99, 41-46.	1.2	15
155	Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. <i>British Journal of Haematology</i> , 1997, 99, 685-691.	1.2	16
156	Conventional induction treatments do not influence overall survival in multiple myeloma. <i>British Journal of Haematology</i> , 1997, 96, 333-337.	1.2	17
157	Use of Modified Functional Assays for Activated Protein C Resistance in Patients with Basally Prolonged aPTT. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1042-1048.	1.8	5
158	Procoagulant Activity of Mononuclear Cells Is Increased in Myeloproliferative and Myelodysplastic Diseases. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1996, 26, 157-163.	0.5	1
159	Combined differentiating therapy for myelodysplastic syndromes: A phase II study. <i>Leukemia Research</i> , 1996, 20, 867-876.	0.4	34
160	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. <i>British Journal of Haematology</i> , 1996, 94, 376-378.	1.2	28
161	Clinical and Immunological Studies in Advanced Cancer Patients Sequentially Treated with Anti CD3 Monoclonal Antibody (OKT3) and Interleukin-2. <i>Leukemia and Lymphoma</i> , 1996, 21, 325-330.	0.6	7
162	Oncogenes in the Pathogenesis of Multiple Myeloma. , 1996, , 169-172.		0

#	ARTICLE	IF	CITATIONS
163	Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. <i>British Journal of Haematology</i> , 1995, 91, 535-543.	1.2	24
164	CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+cells. <i>British Journal of Haematology</i> , 1995, 90, 625-632.	1.2	9
165	Retinoic acid inhibits the growth of human myeloma cells in vitro. <i>British Journal of Haematology</i> , 1995, 89, 555-560.	1.2	15
166	1Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 705-719.	1.1	24
167	Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120. <i>European Journal of Immunology</i> , 1995, 25, 1306-1311.	1.6	40
168	Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. <i>Blood</i> , 1995, 85, 3679-3687.	0.6	66
169	High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. <i>Blood</i> , 1995, 85, 1596-1602.	0.6	133
170	Interferon- β in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 18, 215-219.	0.6	13
171	Haematological support of high-dose sequential chemotherapy: Clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. <i>Annals of Oncology</i> , 1995, 6, S3-S8.	0.6	17
172	T Cells in Multiple Myeloma: Is This a Reliable Population to Count on as Antitumor Effector Cells?. <i>Leukemia and Lymphoma</i> , 1995, 17, 63-70.	0.6	6
173	Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization. <i>Bone Marrow Transplantation</i> , 1995, 16, 223-8.	1.3	23
174	High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 1994, 12, 503-509.	0.8	72
175	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. <i>Leukemia and Lymphoma</i> , 1994, 15, 17-20.	0.6	28
176	Recombinant interferon- β inhibits the in vitro proliferation of human myeloma cells. <i>British Journal of Haematology</i> , 1994, 86, 726-732.	1.2	27
177	Correlation between disease activity and T-cell CD3 chain expression in a B-cell lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 886-888.	1.2	33
178	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. <i>British Journal of Haematology</i> , 1994, 87, 494-502.	1.2	5
179	Molecular characteristics of human plasma, platelet and vascular cell PAI-1. Comparison between normal and thrombocytemic subjects. <i>Fibrinolysis</i> , 1994, 8, 28-30.	0.5	2
180	Recombinant interferon- β in a patient with multiple myeloma. <i>European Journal of Cancer</i> , 1994, 30, 1731.	1.3	1

#	ARTICLE	IF	CITATIONS
181	Classification of patients affected by multiple myeloma using a neural network software. <i>European Journal of Haematology</i> , 1994, 52, 182-183.	1.1	9
182	Selection and characterization of early hematopoietic progenitors using an anti-CD71/S06 immunotoxin. <i>Experimental Hematology</i> , 1994, 22, 166-73.	0.2	5
183	THE MUTATION OF N-RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA. <i>British Journal of Haematology</i> , 1993, 83, 672-673.	1.2	3
184	Microalbuminuria in insulin-dependent diabetes is associated with high levels of prothrombin fragment 1+2. <i>Thrombosis Research</i> , 1993, 72, 541-546.	0.8	9
185	Fibrinolytic Imbalance in Essential Thrombocythemia: Role of Platelets. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1993, 23, 38-44.	0.5	3
186	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	0.6	116
187	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. <i>Blood</i> , 1993, 82, 1787-1797.	0.6	35
188	Interferon plus Glucocorticoids as Intensified Maintenance Therapy Prolongs Tumor Control in Relapsed Myeloma. <i>Acta Haematologica</i> , 1993, 90, 71-76.	0.7	13
189	Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.. <i>Journal of Experimental Medicine</i> , 1993, 178, 1091-1096.	4.2	109
190	Multiple myeloma: "early" plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. <i>British Journal of Haematology</i> , 1993, 85, 504-513.	1.2	29
191	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. <i>Blood</i> , 1993, 81, 2708-2713.	0.6	2
192	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. <i>Blood</i> , 1993, 82, 1787-1797.	0.6	0
193	Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? [letter; comment]. <i>Blood</i> , 1993, 82, 3507-3508.	0.6	2
194	Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. <i>Bone Marrow Transplantation</i> , 1993, 11, 271-7.	1.3	34
195	Co-stimulatory signal delivered by CD73 molecule to human CD45RAhiCD45ROlo (naive) CD8+ T lymphocytes. <i>Journal of Immunology</i> , 1993, 151, 3961-70.	0.4	36
196	Lupus Anticoagulant: Interference with <i>In Vivo</i> Prostaglandin Production and with Platelet Sensitivity to Prostacyclin. <i>Scandinavian Journal of Rheumatology</i> , 1992, 21, 124-128.	0.6	6
197	Manipulating Hemopoietic Progenitors: the Role of High-Dose Chemotherapy and Granulocyte Colony Stimulating Factor. <i>Leukemia and Lymphoma</i> , 1992, 7, 31-31.	0.6	0
198	Cyclosporin A and dipyridamole: An effective combination against the generation of cytotoxic T lymphocytes (CTL). <i>Pharmacological Research</i> , 1992, 26, 12-13.	3.1	0

#	ARTICLE	IF	CITATIONS
199	Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.. Journal of Clinical Oncology, 1992, 10, 1955-1962.	0.8	48
200	Standard Chemotherapy for Myelomatosis: An Area of Great Controversy. Hematology/Oncology Clinics of North America, 1992, 6, 371-382.	0.9	21
201	C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 1992, 80, 733-737.	0.6	265
202	Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture. Leukemia Research, 1992, 16, 743-750.	0.4	2
203	Multiple independent immunoglobulin class-switch recombinations occurring within the same clone in myeloma. British Journal of Haematology, 1992, 82, 676-680.	1.2	13
204	Isoform-specific associations of CD45 with accessory molecules in human T lymphocytes. European Journal of Immunology, 1992, 22, 365-371.	1.6	89
205	Multiple myeloma: Intensified maintenance therapy with recombinant interferon- α 2b plus glucocorticoids. European Journal of Haematology, 1992, 49, 93-97.	1.1	9
206	Sequential administration of OKT3 (anti-CD3) and interleukin-2 in two patients with chemoresistant hematological disease. European Journal of Haematology, 1992, 49, 150-152.	1.1	3
207	C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 1992, 80, 733-737.	0.6	2
208	Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction [letter; comment]. Blood, 1992, 79, 291-292.	0.6	3
209	Maintenance Treatment with Recombinant Interferon Alfa-2b Prolongs Remission and Survival in Patients with Multiple Myeloma Responding to Induction Chemotherapy. , 1992, , 67-72.		0
210	Self-renewal inhibition of acute myeloid leukemia clonogenic cells by biological inducers of differentiation. Leukemia, 1992, 6, 100-6.	3.3	20
211	Human recombinant stem cell factor stimulates in vitro proliferation of acute myeloid leukemia cells and expands the clonogenic cell pool. Leukemia, 1992, 6, 642-8.	3.3	16
212	Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. European Journal of Cancer & Clinical Oncology, 1991, 27, 22-27.	0.9	63
213	Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex [see comments]. Blood, 1991, 78, 1770-1780.	0.6	43
214	Dipyridamole <i>in vitro</i> suppresses the generation of T-cell cytotoxic functions: Synergistic activity with cyclosporine. European Journal of Haematology, 1991, 46, 6-10.	1.1	2
215	Dual rearrangement of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia. European Journal of Haematology, 1991, 46, 71-76.	1.1	6
216	Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma. European Journal of Haematology, 1991, 47, 305-309.	1.1	17

#	ARTICLE	IF	CITATIONS
217	Amplification of T Cell Activation Induced by CD73 (Ecto-5'Nucleotidase) Engagement. <i>Advances in Experimental Medicine and Biology</i> , 1991, 309B, 155-158.	0.8	6
218	Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. <i>Blood</i> , 1990, 76, 1375-1379.	0.6	66
219	Complete remission in multiple myeloma. <i>Lancet, The</i> , 1990, 335, 52-53.	6.3	5
220	Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy. <i>New England Journal of Medicine</i> , 1990, 322, 1430-1434.	13.9	374
221	Alpha-2b recombinant interferon (IntronA) as maintenance treatment in multiple myeloma. <i>European Journal of Haematology</i> , 1990, 45, 9-11.	1.1	0
222	Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. <i>Bone Marrow Transplantation</i> , 1990, 6, 143-5.	1.3	42
223	Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. <i>Blood</i> , 1990, 76, 1375-9.	0.6	11
224	Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. <i>Cancer Research</i> , 1990, 50, 6478-82.	0.4	25
225	Multiple Myeloma: Beta-2-Microglobulin is not a Useful Follow-Up Parameter. <i>Acta Haematologica</i> , 1989, 82, 122-125.	0.7	18
226	Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma. <i>Tumori</i> , 1989, 75, 1-3.	0.6	4
227	Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.. <i>Journal of Clinical Oncology</i> , 1989, 7, 119-125.	0.8	72
228	Effect of two aliphatic aldehydes, methylglyoxal and 4-hydroxypentenal, on the growth of Yoshida ascites hepatoma AH-130. <i>Chemico-Biological Interactions</i> , 1989, 70, 227-240.	1.7	16
229	CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. <i>European Journal of Immunology</i> , 1989, 19, 1037-1044.	1.6	46
230	MACOP-B treatment for advanced stage diffuse large cell lymphoma: A multicenter Italian study. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1441-1449.	0.9	18
231	Paraproteinaemias and platelet aggregation: Role of whole blood aggregometry. <i>Thrombosis Research</i> , 1989, 55, 267-277.	0.8	5
232	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION. <i>Lancet, The</i> , 1989, 334, 580-585.	6.3	676
233	Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. <i>European Journal of Haematology</i> , 1989, 43, 30-34.	1.1	2
234	Granulocyte-macrophage colony-stimulating factor requires interaction with accessory cells or granulocyte-colony stimulating factor for full stimulation of human myeloid progenitors. <i>Blood</i> , 1989, 73, 402-405.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. <i>Cancer Treatment Reviews</i> , 1988, 15, 43-48.	3.4	43
236	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-1068.	0.6	48
237	Human myeloma: Several subsets of circulating lymphocytes express plasma cell-associated antigens. <i>European Journal of Haematology</i> , 1988, 40, 299-304.	1.1	28
238	Biochemical and immunologic abnormalities in peripheral blood T lymphocytes of patients with hemophilia A. <i>European Journal of Haematology</i> , 1988, 41, 334-340.	1.1	5
239	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-1068.	0.6	44
240	Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. <i>Clinical and Experimental Immunology</i> , 1988, 73, 214-8.	1.1	30
241	The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5' nucleotidase activity. <i>Journal of Immunology</i> , 1988, 141, 3768-75.	0.4	15
242	Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5' nucleotidase deficiency. <i>Journal of Clinical & Laboratory Immunology</i> , 1988, 26, 89-95.	0.1	5
243	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-8.	0.6	8
244	Absence of ($\hat{\alpha}$) ³ H]desmethoxyverapamil binding sites on human platelets and lack of evidence for voltage-dependent calcium channels. <i>European Journal of Pharmacology</i> , 1987, 142, 83-91.	1.7	13
245	Cytobiological Studies in Multiple Myeloma. <i>Acta Haematologica</i> , 1987, 78, 41-42.	0.7	2
246	Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies. <i>Acta Haematologica</i> , 1987, 78, 239-242.	0.7	17
247	Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. <i>Leukemia Research</i> , 1987, 11, 265-272.	0.4	14
248	Immunologic and virologic findings in hemophiliacs do not correlate with ecto-5' nucleotidase activity of peripheral blood lymphocytes. A difference with homosexual men. <i>European Journal of Haematology</i> , 1987, 38, 310-314.	1.1	2
249	Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. <i>Clinical and Experimental Immunology</i> , 1987, 69, 426-32.	1.1	14
250	Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. <i>Alabama Journal of Medical Sciences</i> , 1987, 24, 400-4.	0.1	1
251	Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. <i>Haematologica</i> , 1987, 72, 171-5.	1.7	13
252	Cell kinetics of multiple myeloma. <i>Hematologic Pathology</i> , 1987, 1, 137-42.	0.2	3

#	ARTICLE	IF	CITATIONS
253	Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody. <i>Tumori</i> , 1986, 72, 135-137.	0.6	16
254	Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2+/T8+ lymphocytes. <i>Journal of Immunology</i> , 1986, 137, 484-9.	0.4	21
255	Reactive Plasmacytosis. <i>Acta Haematologica</i> , 1985, 73, 108-110.	0.7	20
256	Treatment of multiple myeloma: A randomized study of three different regimens. <i>Leukemia Research</i> , 1985, 9, 1043-1049.	0.4	20
257	Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.. <i>Journal of Clinical Oncology</i> , 1985, 3, 1503-1507.	0.8	8
258	Decreased ecto-5' nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. <i>Blood</i> , 1985, 65, 530-534.	0.6	11
259	Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. <i>British Journal of Haematology</i> , 1984, 58, 689-696.	1.2	91
260	Mixed lymphocyte reaction in human monoclonal gammopathies. <i>Experientia</i> , 1983, 39, 1137-1139.	1.2	0
261	Kinetics of circulating B lymphocytes in human myeloma. <i>Blood</i> , 1983, 61, 812-814.	0.6	35
262	The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. <i>Clinical and Experimental Immunology</i> , 1983, 51, 173-7.	1.1	23
263	Kinetics of circulating B lymphocytes in human myeloma. <i>Blood</i> , 1983, 61, 812-4.	0.6	2
264	Human Myeloma: Kinetics of the Remission Phase. <i>Acta Haematologica</i> , 1982, 68, 237-240.	0.7	15
265	Idiotypic lymphocytes in human monoclonal gammopathies. <i>Annales De L'Institut Pasteur Immunologie</i> , 1981, 132, 9-19.	0.9	22
266	Monitoring of a Long Survival Myeloma Patient. <i>Tumori</i> , 1981, 67, 571-573.	0.6	6
267	Early B lymphocytes in man. <i>Experientia</i> , 1980, 36, 1124-1125.	1.2	3
268	Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 1977, 296, 881-882.	13.9	14
269	B lymphocytes receptors: a new biological approach for immunofluorescence studies. <i>Haematologica</i> , 1977, 62, 221-2.	1.7	2
270	Early recruitment in the human myeloma cell population after cytostatic treatment. <i>Haematologica</i> , 1976, 61, 184-93.	1.7	8

#	ARTICLE	IF	CITATIONS
271	Letter: Alkylating agents and myeloma cells. <i>Blood</i> , 1976, 47, 1056-1057.	0.6	3
272	Myeloid Cell Actinomycin Binding in Human Myeloid Leukaemia. <i>Acta Haematologica</i> , 1974, 51, 1-8.	0.7	1
273	Feulgen hydrolysis of normal and leukemic blood cells. <i>European Journal of Cancer</i> , 1974, 10, 563-566.	1.0	0
274	Actinomycin binding and uridine incorporation by human normal bone marrow cells. <i>Experientia</i> , 1974, 30, 951-952.	1.2	5
275	In vivo kinetic studies in human myeloma. <i>Haematologica</i> , 1974, 59, 10-24.	1.7	17
276	Actinomycin Binding Capacity in Human Leukaemic Lymphoid Cells. <i>Acta Haematologica</i> , 1972, 48, 89-97.	0.7	10
277	Bone Marrow Return and Division of Circulating Acute Lymphoblastic Leukaemia Cells. <i>Acta Haematologica</i> , 1972, 47, 277-282.	0.7	5
278	Lymphocyte actinomycin binding capacity in chronic lymphocytic leukaemia. <i>Experientia</i> , 1972, 28, 1484-1484.	1.2	3
279	The problem of anaemia in the acute leukaemias. <i>European Journal of Cancer</i> , 1970, 6, 33-38.	1.0	9
280	Proliferative Potential of Out-of-cycle Leukaemic Cells. <i>Nature</i> , 1969, 224, 375-376.	13.7	71
281	Unusual blast proliferation and kinetics in acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 1969, 5, 343-348.	1.0	6
282	Changes in protein metabolism in proliferating and non-proliferating human acute leukaemia cells treated with actinomycin-D. <i>Experientia</i> , 1969, 25, 862-863.	1.2	1
283	Different Blast Kinetics in Acute Myeloblastic and Lymphoblastic Leukaemia. <i>Acta Haematologica</i> , 1969, 41, 215-224.	0.7	11
284	Degradation of rapidly labelled RNA in proliferating and non-proliferating human acute leukemia cells. <i>Experientia</i> , 1968, 24, 1267-1268.	1.2	3
285	UNRESPONSIVENESS TO PHYTO-HAËMAGGLUTININ OF ACUTE LYMPHOBLASTIC LEUKAËMIA CELLS. <i>Lancet, The</i> , 1968, 292, 409-410.	6.3	0
286	Characteristics of Cell Proliferation in Children's Lymphoblastic Leukemia. <i>Tumori</i> , 1968, 54, 147-160.	0.6	1
287	Proliferative Activity of the Cells of Acute Leukaemia in Relapse and in Steady State. <i>Acta Haematologica</i> , 1967, 38, 193-199.	0.7	24
288	Presence of Three Philadelphia Chromosomes (Ph1) in the Blastic Crisis of a Case of Chronic Myeloid Leukemia. <i>Tumori</i> , 1967, 53, 315-321.	0.6	5

#	ARTICLE	IF	CITATIONS
289	Proliferation Kinetics of Acute Leukemia Cells in Relation to the Chemotherapy. <i>Acta Geneticae Medicae Et Gemellologiae</i> , 1967, 17, 30-39.	0.1	1
290	Non-self-maintaining Kinetics of Proliferating Blasts in Human Acute Leukaemia. <i>Nature</i> , 1967, 216, 188-189.	13.7	48
291	Cell population kinetics in human acute leukaemia. <i>European Journal of Cancer</i> , 1967, 3, 301-307.	1.0	47
292	Degradation of RNA and changes in protein metabolism in human acute leukaemia cells treated with actinomycin D. <i>Revue Française D'Études Cliniques Et Biologiques</i> , 1967, 12, 986-90.	0.1	1
293	Cytogenetical and proliferative characteristics of acute promyelocytic leukaemia cells. <i>European Journal of Cancer</i> , 1966, 2, 189-192.	1.0	2
294	«In Vivo» Studies on RNA Metabolism of Human Acute Leukemia Cells.. <i>Tumori</i> , 1965, 51, 419-431.	0.6	1
295	X-RAYS AND PHILADELPHIA CHROMOSOME. <i>Lancet, The</i> , 1965, 285, 1336-1337.	6.3	10
296	Proliferation and Maturation Defect in Acute Leukemia Cells. <i>Nature</i> , 1964, 203, 92-94.	13.7	115
297	In vivo Incorporation of Tritiated Thymidine in Acute Leukemia Chromosomes. <i>Nature</i> , 1963, 200, 807-809.	13.7	16
298	Proliferative Capacity of Acute Leukemia Cells. <i>Nature</i> , 1960, 187, 611-612.	13.7	58
299	Radioautographic Investigations on DNA and Protein Metabolism in 2 Cases of Di Guglielmo's Disease. <i>Blood</i> , 1960, 16, 1122-1132.	0.6	21
300	Nucleic Acids and Protein Metabolism in Acute Leukemia Cells. <i>Blood</i> , 1960, 16, 1555-1563.	0.6	47
301	Interrelationship between RNA and protein metabolism in human normal bone marrow cells. <i>Experimental Cell Research</i> , 1960, 20, 645-646.	1.2	4
302	Incorporation of Thymidine labelled with Tritium by Circulating Cells of Infectious Mononucleosis. <i>Nature</i> , 1959, 183, 1691-1692.	13.7	33
303	The effect of administration of 6-mercaptopurine on nucleic acids and alkaline phosphatase of regenerating rat liver. <i>Cancer</i> , 1958, 11, 222-225.	2.0	13
304	Increased transaminase activity in the liver after administration of cortisone. <i>Biochimica Et Biophysica Acta</i> , 1957, 24, 250-254.	1.3	77
305	The effect of cortisone on the glucose-6-phosphatase activity in normal and regenerating rat liver. <i>Clinica Chimica Acta</i> , 1957, 2, 280-283.	0.5	1
306	Biochimica Dei Tessuti Iperplastici: Modificazioni Del Metabolismo Cellulare Indotte Dalla Rigenerazione Epatica. <i>Tumori</i> , 1957, 43, 137-165.	0.6	0